Posts Tagged ‘R&D’
Outlook for Combination Therapies in Retinal Disease
When Regeneron Pharmaceuticals and Bayer announced their collaboration to develop and commercialize a combination therapy using Regeneron’s vascular endothelial growth factor (VEGF) trap aflibercept (Eylea) and its angiopoietin2 (ANG-2) antibody, nesvacumab, it was the latest in a rash of endeavors – at least seven at last count – to marry different compounds and anti-VEGF agents…
Read MoreFrinzi Shares a Bit of His Plans for AMO
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 079″] Following his successful exit from WaveTec, Tom Frinzi joined Abbott as a senior vice president and head of AMO. In this exclusive interview with OIS, Frinzi shares his motivations and what he’d like to see AMO become. 10 Top Topics in this OIS Podcast: Ophthalmology is in his DNA. Spent…
Read MoreMixed Results Don’t Sidetrack Rhopressa Plans
Despite tepid investor response to safety data from the latest comparative trial of its lead-candidate glaucoma agent, Aerie Pharmaceuticals says it is still on track to file a New Drug Application for the agent in the third quarter of this year. However, investors focusing on that data, from the Rocket 1 and 2 trials, may…
Read MoreMuller Explains Departure from Avedro; Opportunity in New Venture
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 071″] David Muller came close to writing the final chapter of Avedro’s push to have corneal cross-linking approved by the FDA. But he opted to leave the company before the final approval came through to pursue a new venture called Allotex. In this interview with OIS Podcast, Muller explains his decision…
Read MoreInotek’s Southwell & McVicar Have Designs on Treating Glaucoma
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 070″] Inotek CEO David Southwell and William K. McVicar PhD Executive Vice President, Chief Scientific Officer, share Inotek’s plan to bring to market a new first-line for glaucoma sufferers. Podcast Guest David P. Southwell Mr. Southwell has been President and CEO since August 2014, and led Inotek through its IPO and…
Read MoreEmptying the OIS Reporter’s Notebook After OIS@AAO
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 069″] OIS Correspondents Michelle Dalton and Richard Kirkner pool their insights on the most compelling sights and insights of OIS, Subspecialty Day and AAO. The two scribes opine on exiting new disease targets, advances in drug delivery, the penetration of digital technology and why the `Pfizergan’ deal makes sense for ophthalmology.…
Read MoreTaking in the View of 2015 & Beyond
This year’s Ophthalmology Innovation Summits are behind us. We’re piling content onto OIS.NET including the 2015 Year in Review by OIS Founder and Co-Chair Emmett Cunningham, MD. And, believe it or not, we’re eagerly accepting registration for our next OIS@ASCRS, which will be held on May 5 at the InterContinental New Orleans. (We are now…
Read MoreWhere Will `Pfizergan’ Fit in Ophthalmology
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 068″] Allergan has been a pillar of the ophthalmology sector for decades so its merger with Pfizer is a cause of concern for some. But ophthalmology leaders also see reason for optimism from the combination. The deal could bring greater firepower to ophthalmology R&D and M&A and some hope it’s a…
Read MoreSaunders Seen As Key Man in Pfizer-Allergan Mashup
Last week, Pfizer and Allergan executives gave us a lot to chew on over the Thanksgiving weekend. The $160 billion combination will create the world’s largest pharmaceutical company, a behemoth comprising at least one element – Allergan – that has had a significant interest in ophthalmology. Allergan – the new Allergan that emerged from the…
Read MoreExploring Novartis’ Interest in Medtech
Reza Zadno, PhD, EIR at InterWest Partners explains his new role at the Novartis Venture Fund. He’ll advise the pharma company on where to commit its considerable dollars in Medtech. Novartis, which own Alcon, historically has invested in Medtech and has done a nice job investing in companies like Zadno’s Visiogen. Speaking With: Reza Zadno…
Read MoreSaunders Promises ‘Greater Impact’ on Ophthalmology
With the planned combination of Pfizer and Allergan to create the world’s largest pharmaceutical company, Brent Saunders, a key player in two significant acquisitions of eye care firms over the past three years, will assume a leading role in the combined company. Saunders, president and CEO of Allergan, will serve as president and COO of…
Read MoreAura Biosciences Offers Hope for Ocular Melanoma
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 067″] Elisabet “Eli” de los Pinos was enjoying her job at Eli Lilly’s Oncology Business Unit where she was part of the leadership team responsible for Alimta’s market launch in Europe, a new drug for the treatment of Lung Cancer. But she took the leap, leaving corporate comfort to build Aura…
Read More